Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., Woerle, H. J.Volume:
15
Language:
english
Journal:
Diabetes, Obesity and Metabolism
DOI:
10.1111/dom.12073
Date:
July, 2013
File:
PDF, 790 KB
english, 2013